The NAC prides itself as a training ground for the next generation of scientists to grow as future leaders in vaccine and monoclonal R&D.
Our goals in this effort are clear: to foster inclusive, sustainable, and impactful partnerships that accelerate progress in vaccine and antibody research and development. By leveraging our expertise, resources, and extensive network, we strive to address pressing health challenges while promoting equity and fairness in the distribution of scientific knowledge and breakthroughs.
Central to the work of the NAC is the establishment of equitable partnerships for scientific collaboration to continuously embolden and increase the capacity for research and scientific leadership from sub-Saharan Africa and India, where many of these infectious diseases are endemic or medically relevant. We provide support for this work in scientific, programmatic, and operational areas to ensure that the regional teams are fully supported and sustainable in achieving major scientific objectives and outcomes.
Our Partners:
- Kenya Medican Research Institute (KEMRI)‐Wellcome Trust Research Programme (KWTRP)
- Kenya AIDS Vaccine Initiative – Institute of Clinical Research (KAVI-ICR)
- Center for Family Health Research (CFHR), Rwanda
- Center for Family Health Research (CFHR), Zambia
- Aurum Institute
- Africa Health Research Institute (AHRI) at University of KwaZulu-Natal
- Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI)
- Cape Town HVTN Immunology Lab (CHIL)
- National Institute for Communicable Diseases (NICD)
- London School of Hygiene and Tropical Medicine (LSHTM)
- Antibody Translational Research Programme (ATRP)
- Indian Institute for Science (IISc), Bangalore, India
- Translational Health and Science Institute (THSTI), New Delhi, India
Our Funders:
- Presidents Emergency Plan for AIDS Relief (PEPFAR) and US Agency for International Development (USAID)
- The Bill & Melinda Gates Foundation